Literature DB >> 21390028

Chemoproteomics quantifies complexity.

Edward B Holson, Stuart L Schreiber.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21390028     DOI： 10.1038/nbt.1804

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  9 in total

1.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.

Authors:  Marcus Bantscheff; Dirk Eberhard; Yann Abraham; Sonja Bastuck; Markus Boesche; Scott Hobson; Toby Mathieson; Jessica Perrin; Manfred Raida; Christina Rau; Valérie Reader; Gavain Sweetman; Andreas Bauer; Tewis Bouwmeester; Carsten Hopf; Ulrich Kruse; Gitte Neubauer; Nigel Ramsden; Jens Rick; Bernhard Kuster; Gerard Drewes
Journal:  Nat Biotechnol       Date:  2007-08-26       Impact factor: 54.908

Review 2.  Histone deacetylase HDAC1/HDAC2-controlled embryonic development and cell differentiation.

Authors:  Reinhard Brunmeir; Sabine Lagger; Christian Seiser
Journal:  Int J Dev Biol       Date:  2009       Impact factor: 2.203

3.  TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin.

Authors:  X F Zheng; D Florentino; J Chen; G R Crabtree; S L Schreiber
Journal:  Cell       Date:  1995-07-14       Impact factor: 41.582

4.  Interaction with AKAP79 modifies the cellular pharmacology of PKC.

Authors:  Naoto Hoshi; Lorene K Langeberg; Christine M Gould; Alexandra C Newton; John D Scott
Journal:  Mol Cell       Date:  2010-02-26       Impact factor: 17.970

5.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.

Authors:  Marcus Bantscheff; Carsten Hopf; Mikhail M Savitski; Antje Dittmann; Paola Grandi; Anne-Marie Michon; Judith Schlegl; Yann Abraham; Isabelle Becher; Giovanna Bergamini; Markus Boesche; Manja Delling; Birgit Dümpelfeld; Dirk Eberhard; Carola Huthmacher; Toby Mathieson; Daniel Poeckel; Valérie Reader; Katja Strunk; Gavain Sweetman; Ulrich Kruse; Gitte Neubauer; Nigel G Ramsden; Gerard Drewes
Journal:  Nat Biotechnol       Date:  2011-01-23       Impact factor: 54.908

Review 6.  Chromatin remodeling, cancer and chemotherapy.

Authors:  Pranab Dey
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

Review 7.  Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.

Authors:  Aleksey G Kazantsev; Leslie M Thompson
Journal:  Nat Rev Drug Discov       Date:  2008-10       Impact factor: 84.694

8.  Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

Authors:  D D Sarbassov; Siraj M Ali; Do-Hyung Kim; David A Guertin; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Curr Biol       Date:  2004-07-27       Impact factor: 10.834

9.  A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p.

Authors:  J Taunton; C A Hassig; S L Schreiber
Journal:  Science       Date:  1996-04-19       Impact factor: 47.728
  9 in total
  1 in total

Review 1.  Epigenetics: A primer for clinicians.

Authors:  Benjamin E Paluch; Abdul R Naqash; Zachary Brumberger; Michael J Nemeth; Elizabeth A Griffiths
Journal:  Blood Rev       Date:  2016-02-26       Impact factor: 8.250
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.